CoChat

A framework for advancing our understanding of cancer-associated fibroblasts

Open access

The DOI matches its Crossref record; 178 of the 182 references it cites were found in a registry or an index; 114 of the 165 sources its claims cite were checked for support.

Abstract

Cancer-associated fibroblasts (CAFs) are a key component of the tumour microenvironment with diverse functions, including matrix deposition and remodelling, extensive reciprocal signalling interactions with cancer cells and crosstalk with infiltrating leukocytes. As such, they are a potential target for optimizing therapeutic strategies against cancer. However, many challenges are present in ongoing attempts to modulate CAFs for therapeutic benefit. These include limitations in our understanding of the origin of CAFs and heterogeneity in CAF function, with it being desirable to retain some antitumorigenic functions. On the basis of a meeting of experts in the field of CAF biology, we summarize in this Consensus Statement our current knowledge and present a framework for advancing our understanding of this critical cell type within the tumour microenvironment.

Overview

CoChat Summary

## TL;DR

This Consensus Statement argues that cancer-associated fibroblasts (CAFs) are important, heterogeneous regulators of the tumour microenvironment and that better definitions, standardized assays, and metadata reporting are needed to make CAF-targeted therapy clinically useful. It emphasizes that CAFs can have both pro- and antitumorigenic effects, so future strategies should focus on CAF subtypes, interconvertibility, and function rather than blanket ablation.

## Key findings

  • CAFs have diverse functions in tumour biology, including matrix deposition/remodeling, reciprocal signalling with cancer cells, crosstalk with leukocytes, effects on angiogenesis, tumour mechanics, drug access, and therapy response.
  • The paper states that the consensus is that most CAFs likely arise from activation of local tissue-resident fibroblasts, but clear examples of alternative origins also exist.
  • Evidence supports CAF heterogeneity and plasticity: recurrent CAF states include matrix-producing contractile myoCAFs and immunomodulatory iCAFs; in pancreatic cancer, proximal CAFs show high TGFβ-driven αSMA and distal CAFs express higher IL-6.
  • The authors note that preclinical and correlative studies suggest improved treatment strategies may be possible by targeting CAFs, and say several clinical trials are underway; they also mention that a Hedgehog-pathway pancreatic cancer trial (NCT01130142) failed and reported decreased patient survival with gemcitabine.

## Methods

  • Consensus Statement based on a Banbury Center meeting at Cold Spring Harbor Laboratory in March 2019, with an open discussion among participants and subsequent drafting, circulation, feedback, and refinement by the authors.
  • The paper synthesizes findings from functional analyses in preclinical models, correlative analyses of patient material, mouse lineage-tracing studies, single-cell technologies, and clinical trial experience.
  • Main analysis is qualitative and conceptual: it reviews CAF origin, activation, heterogeneity, function, and targeting, then proposes methodological recommendations for nomenclature, metadata, and assay standardization.

## Limitations

  • The paper states that lack of precision around fibroblast-specific markers makes it difficult to define CAFs and to determine their exact origin.
  • It states that longitudinal sampling of the same human lesion is rarely possible, making it hard to directly track CAF state conversion in patients.
  • Evident from the text: much of the discussion is based on heterogeneous preclinical models, correlative patient studies, and expert consensus rather than a single systematic empirical study of CAFs (this is evident from the paper’s format and described approach).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41568-019-0238-1

Cites

178 of 178 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Diverse mechanisms of cancer-associated fibroblast activation. This schematic highlights the multiple mechanisms that can contribute to cancer-associated fibroblast (CAF) activation. FGF, fibroblast growth factor; PDGF, platelet-derived growth factor; ROS, reactive oxygen species; RTK, receptor tyrosine kinase; TGFβ, transforming growth factor-β; TNF, tumour necrosis factor.
Fig. 1 Diverse mechanisms of cancer-associated fibroblast activation. This schematic highlights the multiple mechanisms that can contribute to cancer-associated fibroblast (CAF) activation. FGF, fibroblast growth factor; PDGF, platelet-derived growth factor; ROS, reactive oxygen species; RTK, receptor tyrosine kinase; TGFβ, transforming growth factor-β; TNF, tumour necrosis factor.CC BY · PubMed Central
Fig. 2 Summary of cancer-associated fibroblast functions and the mechanisms by which they are achieved. Dark blue text boxes indicate the biological functions being regulated, with light blue, green, purple and grey text boxes indicating the processes and mechanisms leading to the control of function. Lines connect mechanisms to functions. Both matrix remodelling and the production of soluble factors contribute to increased tumour cell invasion. Soluble factors also contribute to changes in tumour growth and the immune microenvironment, which is also affected by the altered metabolic state of the tumour. CAF, cancer-associated fibroblast; CCL2, CC-chemokine ligand 2; CXCL12, CXC-chemokine ligand 12; IL-6, interleukin-6; GAS6, growth arrest-specific protein 6; HGF, hepatocyte growth factor; TGFβ, transforming growth factor-β; VEGF, vascular endothelial growth factor.
Fig. 2 Summary of cancer-associated fibroblast functions and the mechanisms by which they are achieved. Dark blue text boxes indicate the biological functions being regulated, with light blue, green, purple and grey text boxes indicating the processes and mechanisms leading to the control of function. Lines connect mechanisms to functions. Both matrix remodelling and the production of soluble factors contribute to increased tumour cell invasion. Soluble factors also contribute to changes in tumour growth and the immune microenvironment, which is also affected by the altered metabolic state of the tumour. CAF, cancer-associated fibroblast; CCL2, CC-chemokine ligand 2; CXCL12, CXC-chemokine ligand 12; IL-6, interleukin-6; GAS6, growth arrest-specific protein 6; HGF, hepatocyte growth factor; TGFβ, transforming growth factor-β; VEGF, vascular endothelial growth factor.CC BY · PubMed Central

Verification

Claims the paper makes

62 Valid · 6 Not valid · 23 Not checked · 7 Own results and interpretations

42 more claims · 29 with their cited sources checked

Create a free account to see all 98 claims and to verify the 3 references still open.

See all claims — free account
  • Probably not a substantial claim. 17
  • It may state two separate claims as one. 42

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 178 references

Research works printed but not linked: 1

  1. Schneider C. A. et al. in Second Harmonic Generation Imaging (eds Pavone, F.S. & Campagnola, P.J.) 373–390 (Taylor & Francis, 2013).

Cited by

See all 3,863

Metadata

Authors
Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D. G., Egeblad, M., Evans, R. M., Fearon, D., Greten, F. R., Hingorani, S. R., Hunter, T., Hynes, R. O., Jain, R. K., Janowitz, T., Jorgensen, C., Kimmelman, A. C., Kolonin, M. G., Maki, R. G., Powers, R. S., Puré, E., Ramirez, D. C., Scherz-Shouval, R., Sherman, M. H., Stewart, S., Tlsty, T. D., Tuveson, D. A., Watt, F. M., Weaver, V., Weeraratna, A. T., & Werb, Z.
Affiliations
  • The Francis Crick Institute (GB)
  • Fox Chase Cancer Center (US)
  • Washington University in St. Louis (US)
  • Cold Spring Harbor Laboratory (US)
  • Salk Institute for Biological Studies (US)
  • Goethe University Frankfurt (DE)
  • Fred Hutch Cancer Center (US)
  • Koch Institute for Integrative Cancer Research At MIT (US)
  • Harvard University (US)
  • Northwell Health (US)
  • NYU Langone Health (US)
  • Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (US)
  • University of Pennsylvania (US)
  • Oregon Health & Science University (US)
  • University of California, San Francisco (US)
  • Guy's Hospital (GB)
  • Johns Hopkins Medicine (US)
Corresponding author
Sahai, Erik
Venue
Nature Reviews Cancer
Published
2020-01-24
Volume
20
Issue
3
Pages
174-186
ISSN
  • 1474-175X (ISSN-L)
  • 1474-1768
OpenAlex
W3003058300
Cited by
3,863
References
182
Citations by year
2026: 554 · 2025: 626 · 2024: 686 · 2023: 652 · 2022: 647 · 2021: 498 · 2020: 193
FWCI
53.90
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature reviews. Cancer (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
  • Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (submittedVersion)
  • DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
  • eScholarship (California Digital Library) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • Figshare (submittedVersion, cc-by)
  • The Francis Crick Institute (cc-by)
Funders
  • U.S. Department of Defense (W81XWH1410240, W81XWH-16, DE-AC02-05CH11231, W81XWH, W81XWH‐14, U01CA210240)
  • Howard Hughes Medical Institute (DE-AC02-05CH11231, W81XWH-14-1-0240)
  • March of Dimes Foundation
  • V Foundation for Cancer Research (P01CA117969)
  • National Foundation for Cancer Research (R35-CA197743, R01-CA208205)
  • Pancreatic Cancer Action Network
  • Advanced Medical Research Foundation (R35-CA197743, R01-CA208205)
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • Lustgarten Foundation (U01CA224013, SU2C-AACR-DT-20-16, 1R01CA188134, P20CA192996, U01CA210240, 5P50CA101955, 5P30CA45508, 1R01CA190092)
  • Wellcome Trust (Z/17/Z, 206439, FC001144, 206439/Z/17/Z)
  • Francis Crick Institute (10144, FC001144)
  • Thompson Family Foundation
  • Northwell Health
  • Greenfield Foundation
  • Sarcoma Alliance for Research through Collaboration
  • Cancer Research UK (12905, 19258, SU2C-AACR-DT-20-16, FC001144, A19258, C219/A23522)
  • Deutsche Forschungsgemeinschaft (DE-AC02-05CH11231, Gr1916/11-1, FOR 2438)
  • Israel Science Foundation (401/17, 1384/1)
  • National Institutes of Health (DE-AC02–05CH11231, U01 CA224173, W81XWH, project 2, 17-85-HING, CA-06927, PO1 CA107584, 5P30CA45508, P30CA045508, 5p30ca045508-35, W81XWH-14-1-0240)
  • Stand Up To Cancer (SU2C-AACR-DT-20-16)
  • Pfizer Pharmaceuticals
  • Ludwig Center at Harvard
  • Medical Research Council (401/17, FC001144, DE-AC02-05CH11231)
  • Engineering and Physical Sciences Research Council (DE-AC02-05CH11231)
  • Biotechnology and Biological Sciences Research Council
  • National Cancer Institute (CA231252, U01CA224193, P20CA192996, U01CA199315, CA130919, R01CA207935, P01CA114046, R01CA244938, CA64872, P50CA101955, R21CA231252, R01CA188134, U10CA180944, PO1 CA107584, R01CA188430, R01CA130919, 17-85-HING, U01CA224173, CA199315, R21CA216745, P50CA196510, U01CA224013, U01CA224348, P20CA192994, R01CA174746, CA107584, 5P30CA45508, P01CA217805, R01CA188048, CA197743, CA143803, P30-CA045508, U54CA143803, DE-AC02-05CH11231, R35CA232124, R01CA232256, P01CA107584, R01CA177670, R35CA197743, R01CA203890, R01CA208205, U2CCA223303, R01CA157490, R01CA223483, CA 59831, R01CA217206, P30CA006927, R01CA161112, P30CA014195, P01CA117969, U01CA210240, P30CA010815, P30CA006973, CA06927, R01CA190092)
  • National Institute of General Medical Sciences (R01GM095567)
  • Lawrence Berkeley National Laboratory (AC02‐05CH11231, DE-AC02-05CH11231, 05CH11231)
  • H2020 European Research Council (754320)
  • U.S. Army Medical Research Acquisition Activity
Topics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Keywords
cancer-associated fibroblasts, tumor microenvironment, extracellular matrix remodeling, CAF heterogeneity, CAF origin
MeSH terms
Cell Plasticity, Cancer-Associated Fibroblasts, Animals, Clinical Trials as Topic, Disease Susceptibility, Humans, Neoplasms, Signal Transduction, Biomarkers, Treatment Outcome, Stromal Cells, Molecular Targeted Therapy, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A framework for advancing our understanding of cancer-associated fibroblasts. https://app.cochat.ai/papers/10.1038/s41568-019-0238-1
The paper
Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D. G., Egeblad, M., Evans, R. M., Fearon, D., Greten, F. R., Hingorani, S. R., Hunter, T., Hynes, R. O., Jain, R. K., Janowitz, T., Jorgensen, C., Kimmelman, A. C., Kolonin, M. G., Maki, R. G., Powers, R. S., Puré, E., . . . Werb, Z. (2020). A framework for advancing our understanding of cancer-associated fibroblasts. Nature Reviews Cancer. https://doi.org/10.1038/s41568-019-0238-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.